Fixed-combination treatments for intraocular hypertension in Chinese patients – focus on bimatoprost-timolol

Figures & data

Table 1 Mean IOP change from baseline, by bimatoprost therapy, in Chinese patients at the 3-month visit

	Prior therapy	N	Baseline IOP (mmHg)	IOP reduction (mmHg)	% reduction
Bima mt	None	89	24.6±4.4	8.0±3.7***	32.0±11.8
	PGA mt	33	18.6±3.4	1.9±2.8***	9.5±13.2
	Non-PGA mt	67	19.8±4.0	4.1±3.5***	18.9±16.1
Bima comb	PGA comb	18	21.4±5.3	5.3±5.1***	21.7±19.5
	Non-PGA comb	33	23.6±5.7	6.4±6.1***	24.8±20.2

Notes:

*** P<0.001 compared with baseline IOP in this group, using paired-sample t-test or Wilcoxon’s signed rank test. Data are presented as mean ± SD.

Abbreviations: Bima, bimatoprost; comb, combination; IOP, intraocular pressure; mt, monotherapy; PGA, prostaglandin analog; SD, standard deviation.

Table 2 The comparison of efficacy of BTFC and unfixed combinations in Chinese patients

Visit time	ITT		PP
	BTFC (n=121)	Unfixed combo (n=114)	BTFC (n=106)	Unfixed combo (n=101)
Baseline
IOP (mmHg)	25.20±3.06	24.87±3.88	25.16±3.0	24.63±2.93
P-value between group	>0.05		>0.05
IOP (mmHg)	15.83±4.21	15.95±5.51	15.18±3.40	14.85±3.36
IOP change (mmHg)	−9.38±4.66	−8.93±4.25	−9.98±4.21	−9.79±3.40
	**	**	**	**
Week 4
% reduction	37.2	33.7	39.67	39.75
Between-group difference	−0.556 (−1.68, 0.57)		−0.261 (−1.30, 0.78)
(95% CI) (mmHg)	P=0.330		P=0.621

Notes:

** P<0.01 compared with baseline IOP in this group, using paired-sample t-test.

Abbreviations: %, IOP reduction percentage; BTFC, bimatoprost-timolol fixed combination; CI, confidence interval; IOP, intraocular pressure; ITT, intent-to-treat population; PP, per-protocol population.

Table 3 The comparison of adverse events of BTFC and unfixed combinations in Chinese patients

	BTFC	Unfixed comb
	(n=121)	(n=114)
Pts with AE (%)	32 (26.45%)	35 (30.70%)
Pts with treatment-related AE (%)	25 (20.66%)	27 (23.68%)
Conjunctival hyperemia	20 (16.53%)	21 (18.42%)
Eye pain	2 (1.65%)	6 (5.26%)
AE caused withdraw	0	2 (1.75%)
SAE	0	2 (1.75%)

Abbreviations: AE, adverse event; BTFC, bimatoprost-timolol fixed combination; comb, combination; Pts, patients; SAE, severe adverse event.

Figure 1 Change in persistence rates according to number of antiglaucoma drops administrated in a Beijing and Shanghai survey (Sun X et al, unpublished data, 2007).

Table 4 PGA and PGA-timolol fixed-combination monotherapy bottle contents and costs for the People’s Republic of China

	BTFC	LTFC	Bima	Latan	Trava
Total fill (mL)	3.08±0.05	2.65±0.04	3.08±0.05	2.65±0.04	2.55±0.1
Drop count	103±2.49	90±7.58	103±2.49	90±7.58	94±2.20
Vol per drop (mL)	0.030±0.000	0.030±0.003	0.030±0.000	0.030±0.003	0.030±0.001
Prod price ($)	28.3	39.8	27.7	34.9	36
Annual cost ($)	200	323	196	283	277
Daily cost ($)	0.549	0.885	0.536	0.774	0.76

Notes: Data are presented as mean ± SD. $ refers to USD.

Abbreviations: Bima, bimatoprost; BTFC, bimatoprost-timolol fixed combination; Latan, latanoprost; LTFC, latanoprost-timolol fixed combination; PGA, prostaglandin analog; Prod, product; Trava, travoprost; Vol, volume.